Director/PDMR Shareholding

RNS Number : 1173G
Dechra Pharmaceuticals PLC
27 February 2018
 

 

 

 

27 February 2018

 

Dechra Pharmaceuticals PLC

(the Company)

Director Shareholding

 

 

Dechra Pharmaceuticals PLC has been notified that on 26 February 2018 Lawson Macartney, Non-Executive Director, purchased 2,940 American Depositary Receipts (ADRs) in the Company at a price of US$68 each. This is equivalent to 5,880 ordinary shares in the Company.

 

Following this acquisition, Lawson Macartney's beneficial interest in the Company is 5,880 shares (0.006% of the current issued share capital).

 

The Notification of Dealing Form set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Lawson Macartney

 

2.

Reason for the notification

a)

Position/status

Director

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

American Depositary Receipts (ADRs) in Dechra Pharmaceuticals PLC (each ADR represents 2 ordinary shares

 

DPHAY/CUSIP: 243435-10-4

b)

Nature of the transaction

Purchase of ADRs

c)

Price(s) and volumes(s)

Price(s)

$68

2,940

d)

Aggregated information

-   Aggregate volume

-   Price

-   Total

 

 

2,940

 

$68

$199,920

e)

Date of the transaction

2018-02-27

f)

Place of the transaction

United States

 

 

 

For further information, please contact:

 

Melanie Hall, Company Secretary             

Telephone number: 01606 814730

 

 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFKODDQBKDPBB
UK 100

Latest directors dealings